Chronic GVHD Response Measures Validation

Graft vs Host Disease Clinical Trial

Official title:

Chronic GVHD Response Measures Validation

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT01902576
• Other study ID #: 2710.00
• Secondary ID: RG1000980
• Status: Active, not recruiting
• Start date: June 2013
• Est. completion date: February 2026

Study information

• Verified date: March 2024
• Source: Fred Hutchinson Cancer Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to develop and validate endpoint measures that can accurately determine whether patients are responding to treatment for chronic Graft-versus-Host Disease (GVHD). Hopefully, this will also lead to being better able to predict which patients will respond to what therapies.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 383
• Est. completion date: February 2026
• Est. primary completion date: September 26, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 7 Years to 99 Years

Eligibility

Inclusion Criteria:

• Age 7 years or older

• Prior first allogeneic stem cell transplant, with any graft source, donor type, and GVHD prophylaxis.

• Diagnosis of chronic GVHD according to the criteria of the diagnosis and scoring group of the NIH consensus conference (Patient must have at least one diagnostic manifestation of chronic GVHD or one distinctive manifestation with pathological confirmation of the diagnosis. Concurrent acute GVHD manifestations will be allowed as long as at least one classic chronic manifestation is present.)

• Initiation of a new systemic treatment for chronic GVHD in the past 4 weeks or anticipated within the next 4 weeks. Systemic treatment is defined as any medication or intervention that has intended systemic effects, including extracorporeal photopheresis, regardless of prior lines of therapy or prior treatment with the agent(s). If a patient is restarting a treatment to which they were previously exposed, they must have been off of it for at least 4 weeks before restarting.

• No evidence of persistent or progressive malignancy at the time of enrollment

• Evaluation at the transplant center at the time of study enrollment, and agreement to be re-evaluated at the transplant center up to four subsequent times: at 3 months, 6 months, and 18 months after enrollment and once if another treatment is added for chronic GVHD.

• Signed, informed consent

Exclusion Criteria:

• Inability to comply with study procedures

• Complete resolution of chronic GVHD at the time of enrollment (patient must have some measurable chronic GVHD activity)

Related Conditions & MeSH terms

• Graft vs Host Disease

Locations

Country	Name	City	State
United States	Fred Hutchinson Cancer Research Center	Seattle	Washington

Sponsors (1)

Lead Sponsor	Collaborator
Fred Hutchinson Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Develop and validate the Chronic GVHD-Activity Index (CGVHD-AI) as a measure of treatment response.	This measure is intended to capture impairments caused by chronic GVHD. We expect that change in the CGVHD-AI could be used to measure treatment response because it will correlate with clinically significant changes reported by physicians and patients. The CGVHD-AI would be most appropriate for use in clinical trials where the goal is symptom relief and decreased disease activity.	18 months
Secondary	To develop and validate the Chronic GVHD Failure-Free Survival Score (CGVHD-FFS) as a predictor of failure-free survival.	This measure is intended for use as an intermediate endpoint that predicts subsequent failure-free survival, defined as absence of death, relapse and requirement for new therapy, i.e., events that constitute treatment failures in clinical trials. The CGVHD-FFS would be most appropriate for phase II and III trials testing agents intended to change the underlying biology of the syndrome, for example by inducing immunologic tolerance.	18 months